The Retinoblastoma Gene Undergoes Rearrangements in <i>BRCA1</i> -Deficient Basal-like Breast Cancer
Göran Jönsson(Lund University), Åke Borg, Cecilia Hegardt(Lund University), Lao H. Saal(Domos (Norway)), Markus Ringnér(Lund University), Päivi Heikkilä(University of Helsinki), Oskar T. Johannsson(Lapland Central Hospital), Johan Vallon‐Christersson(Lund University), Mårten Fernö(Lund University), C. Persson(Lund University), Aðalgeir Arason(University of Iceland), Johan Staaf(Lund University), Bjarni A. Agnarsson(Reykjavík University), Heli Nevanlinna(University of Helsinki), Rósa B. Barkardóttir(University of Iceland), Rainer Fagerholm(358 (Finland)), Dorthe Grabau(Lund University), Sofia K. Gruvberger-Saal(Lund University), Niklas Loman(Lund University), Ellinor Johnsson(University of Iceland), Karolina Holm(Lund University), Håkan Olsson(Nokia (Finland)), Kristina Lövgren(Lund University), Linda Magnusson(University of Iceland)
Cited by 50
Related Papers
Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
|The American Journal of Human Genetics|2003|3.7k
Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks
|Nature Medicine|2001|2.7k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k